USANA Health Sciences (USNA) said Monday the clinical study for its skin treatment Celavive Resurfacing Serum showed statistically significant improvements in the users' skin appearance and was well tolerated by all subjects.
The clinical study, which was done over 12 weeks to assess the efficacy and tolerance of the product, included 33 women with mild to moderate skin concerns, the company said.
Price: 24.77, Change: +0.03, Percent Change: +0.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.